Extendicare (TSE:EXE – Get Free Report) had its target price upped by stock analysts at National Bank Financial from C$32.00 to C$34.00 in a research report issued on Tuesday,BayStreet.CA reports. The firm currently has an “outperform” rating on the stock. National Bank Financial’s target price suggests a potential upside of 6.35% from the stock’s previous close.
Other analysts have also issued reports about the stock. BMO Capital Markets upped their price target on shares of Extendicare from C$24.00 to C$30.00 in a research note on Monday, March 2nd. TD Securities raised shares of Extendicare from a “hold” rating to a “buy” rating and increased their target price for the company from C$19.00 to C$32.00 in a research note on Monday, April 6th. Desjardins set a C$34.50 target price on shares of Extendicare and gave the company a “buy” rating in a research note on Wednesday, April 22nd. TD increased their target price on shares of Extendicare from C$32.00 to C$39.00 and gave the company a “buy” rating in a research note on Monday. Finally, Canadian Imperial Bank of Commerce increased their target price on shares of Extendicare from C$22.00 to C$32.00 in a research note on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of C$31.00.
View Our Latest Stock Analysis on EXE
Extendicare Stock Performance
Extendicare (TSE:EXE – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported C$0.42 earnings per share (EPS) for the quarter. Extendicare had a return on equity of 45.35% and a net margin of 6.99%.The business had revenue of C$465.22 million during the quarter. As a group, analysts predict that Extendicare will post 0.6134729 EPS for the current fiscal year.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Stories
- Five stocks we like better than Extendicare
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
- Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
